Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Verekitug in Chronic Obstructive Pulmonary Disease (COPD). The expected timing is based on the latest available company guidance and may change.
VENTURE trial. 7/8/25- First patient dosed in Ph2. 11/5/25- Ongoing enrollment. 02/11/26:- VENTURE Ph2 COPD trial has enrolled more than 60% of patients; enrollment continues. 03/26/26:- VENTURE Ph2 COPD trial remains over 60% enrolled with ongoing recruitment for extended-interval arms. 05/13/26:- VENTURE Ph2 COPD enrollment >400; enrollment capped going forward. Placebo-controlled efficacy data now expected H2 2027. 08/11/26:- VENTURE enrollment completed with 481 participants. Ph2 data still expected H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.